Global Health Data Exchange - Discover the World's Health Data

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Nav

General Info
Geography 
Australia (AUS)
Belgium (BEL)
Bulgaria (BGR)
Croatia (HRV)
Czech Republic
Denmark (DNK)
Estonia (EST)
Finland (FIN)
France (FRA)
Germany (DEU)
Greece (GRC)
Hungary (HUN)
Italy (ITA)
Latvia (LVA)
Lithuania (LTU)
Poland (POL)
Romania (ROU)
Slovakia (SVK)
Spain (ESP)
Sweden (SWE)
Ukraine (UKR)
Time period covered 
01/2001 - 12/2008